BE879489A - Compositions pharmaceutiques antiracteriennes et leur methode d'utilisation - Google Patents

Compositions pharmaceutiques antiracteriennes et leur methode d'utilisation Download PDF

Info

Publication number: BE879489A
Authority: BE; Belgium
Prior art keywords: emi; acid; pharmaceutical composition; composition according; strains
Prior art date: 1978-10-20

Application number

BE0/197705A

Other languages

English (en)

French (fr)

Original Assignee

Ausonia Farma Srl

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-10-20

Filing date

1979-10-18

Publication date

1980-02-15

1979-10-18 Application filed by Ausonia Farma Srl filed Critical Ausonia Farma Srl

1980-02-15 Publication of BE879489A publication Critical patent/BE879489A/fr

Links

239000008194 pharmaceutical composition Substances 0.000 title claims description 14
238000000034 method Methods 0.000 title description 4
239000000203 mixture Substances 0.000 claims description 19
KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 claims description 12
230000003115 biocidal effect Effects 0.000 claims description 12
MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 claims description 12
229960000210 nalidixic acid Drugs 0.000 claims description 11
229960000321 oxolinic acid Drugs 0.000 claims description 11
229950006669 cefalexin pivoxil Drugs 0.000 claims description 9
DIGADQKVPFDJSI-SPYBWZPUSA-N cefalexin pivoxil Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(=O)OCOC(=O)C(C)(C)C)=CC=CC=C1 DIGADQKVPFDJSI-SPYBWZPUSA-N 0.000 claims description 9
150000001875 compounds Chemical class 0.000 claims description 9
JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 claims description 7
230000000844 anti-bacterial effect Effects 0.000 claims description 5
229960001732 pipemidic acid Drugs 0.000 claims description 5
RCIMBBZXSXFZBV-UHFFFAOYSA-N piromidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCCC1 RCIMBBZXSXFZBV-UHFFFAOYSA-N 0.000 claims description 5
229960004444 piromidic acid Drugs 0.000 claims description 4
ACXMTAJLYQCRGF-PBFPGSCMSA-N cefatrizine Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](N)C=2C=CC(O)=CC=2)CC=1CSC1=CN=N[N]1 ACXMTAJLYQCRGF-PBFPGSCMSA-N 0.000 claims description 2
229960002420 cefatrizine Drugs 0.000 claims description 2
208000035143 Bacterial infection Diseases 0.000 claims 1
208000022362 bacterial infectious disease Diseases 0.000 claims 1
230000002401 inhibitory effect Effects 0.000 description 16
239000000243 solution Substances 0.000 description 13
229940106164 cephalexin Drugs 0.000 description 11
ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 11
239000003242 anti bacterial agent Substances 0.000 description 9
230000000694 effects Effects 0.000 description 7
229940088710 antibiotic agent Drugs 0.000 description 5
230000001580 bacterial effect Effects 0.000 description 4
UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
229960004621 cinoxacin Drugs 0.000 description 3
VDUWPHTZYNWKRN-UHFFFAOYSA-N cinoxacin Chemical compound C1=C2N(CC)N=C(C(O)=O)C(=O)C2=CC2=C1OCO2 VDUWPHTZYNWKRN-UHFFFAOYSA-N 0.000 description 3
244000000058 gram-negative pathogen Species 0.000 description 3
244000000059 gram-positive pathogen Species 0.000 description 3
-1 pivaloyloxymethyl ester Chemical class 0.000 description 3
238000002211 ultraviolet spectrum Methods 0.000 description 3
238000009631 Broth culture Methods 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
125000005331 diazinyl group Chemical group N1=NC(=CC=C1)* 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
238000002955 isolation Methods 0.000 description 2
244000052769 pathogen Species 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
241000194107 Bacillus megaterium Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
241001103259 Baltimora Species 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
240000001817 Cereus hexagonus Species 0.000 description 1
241000194032 Enterococcus faecalis Species 0.000 description 1
241001331845 Equus asinus x caballus Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
241000588747 Klebsiella pneumoniae Species 0.000 description 1
208000032420 Latent Infection Diseases 0.000 description 1
239000004104 Oleandomycin Substances 0.000 description 1
RZPAKFUAFGMUPI-UHFFFAOYSA-N Oleandomycin Natural products O1C(C)C(O)C(OC)CC1OC1C(C)C(=O)OC(C)C(C)C(O)C(C)C(=O)C2(OC2)CC(C)C(OC2C(C(CC(C)O2)N(C)C)O)C1C RZPAKFUAFGMUPI-UHFFFAOYSA-N 0.000 description 1
206010034133 Pathogen resistance Diseases 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
241000588769 Proteus <enterobacteria> Species 0.000 description 1
241000589517 Pseudomonas aeruginosa Species 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
241000607715 Serratia marcescens Species 0.000 description 1
241000607768 Shigella Species 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical class N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
239000000463 material Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
RZPAKFUAFGMUPI-KGIGTXTPSA-N oleandomycin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C RZPAKFUAFGMUPI-KGIGTXTPSA-N 0.000 description 1
235000019367 oleandomycin Nutrition 0.000 description 1
229960002351 oleandomycin Drugs 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BE0/197705A 1978-10-20 1979-10-18 Compositions pharmaceutiques antiracteriennes et leur methode d'utilisation BE879489A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT28934/78A IT1119708B (it)	1978-10-20	1978-10-20	Impiego di beta-chetoacidi eterociclici azotati come inibitori del trasferimento di fattori genetici di resistenza

Publications (1)

Publication Number	Publication Date
BE879489A true BE879489A (fr)	1980-02-15

Family

ID=11224798

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE0/197705A BE879489A (fr)	1978-10-20	1979-10-18	Compositions pharmaceutiques antiracteriennes et leur methode d'utilisation

Country Status (3)

Country	Link
JP (1)	JPS5573612A (2)
BE (1)	BE879489A (2)
IT (1)	IT1119708B (2)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69019395D1 (de)	1989-02-21	1995-06-22	Banyu Pharma Co Ltd	Zusammensetzung gegen Mikroben.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date
HU167910B (2) *	1972-11-22	1976-01-28
JPS5745219B2 (2) *	1972-12-18	1982-09-27
JPS5750783B2 (2) *	1974-02-07	1982-10-28

1978
- 1978-10-20 IT IT28934/78A patent/IT1119708B/it active
1979
- 1979-10-17 JP JP13412479A patent/JPS5573612A/ja active Granted
- 1979-10-18 BE BE0/197705A patent/BE879489A/fr not_active IP Right Cessation

Also Published As

Publication number	Publication date
IT7828934A0 (it)	1978-10-20
JPS6250448B2 (2)	1987-10-24
IT1119708B (it)	1986-03-10
JPS5573612A (en)	1980-06-03

Legal Events

Date

Code

Title

Description

1990-04-30

RE

Patent lapsed

Owner name: AUSONIA FARMACEUTICI S.R.L.

Effective date: 19891031

Publication	Publication Date	Title
KR0180798B1 (ko)	1999-03-20	결정성 페니실린 유도체, 그의 제법 및 용도
Chain et al.	1942	An antibacterial substance produced by Penicillium claviforme
FR2482967A1 (fr)	1981-11-27	Nouveaux derives de l'imidazo-rifamycine, leur procede de preparation et leur application en therapeutique
FR2953138A1 (fr)	2011-06-03	Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus
WO2006120494A1 (fr)	2006-11-16	Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l’eugenol, le borneol et les carvacrol
FR2498931A1 (fr)	1982-08-06	Medicament constitue par l'acide ethyl-1 fluoro-6 piperazinyl-7 oxo-4 dihydro-1,4 quinoleine-3 carboxylique et ses sels d'addition d'acides non toxiques pharmaceutiquement acceptables
US4386070A (en)	1983-05-31	Pharmaceutical compositions endowed with an antibacterial activity and their use in the treatment of infections due to gram-positive and gram-negative pathogens
Panwalker et al.	1976	Efficacy of cinoxacin in urinary tract infections
JPH06500320A (ja)	1994-01-13	２―（２―ブロモ―２―ニトロエテニル）フランと２―ブロモ―２―ニトロプロパン―１，３―ジオールとの新しい協力作用組成物及びその利用
DE2629926A1 (de)	1977-01-20	Clavulansaeureamide, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneipraeparate
BE818335R (fr)	1975-01-31	Composition antibacterienne et procede
FR2591598A1 (fr)	1987-06-19	Nouveaux derives d'acide ceph-3-em-4-carboxylique, leur preparation et medicaments les contenant
CN109928880A (zh)	2019-06-25	一种紫苏氧基羰基丙酸乙酯及其应用
BE825937A (fr)	1975-08-25	Compositions antibacteriennes comprenant un compose de cephalosporine et un compose de penicilline
JPH03218383A (ja)	1991-09-25	光学活性キノリンカルボン酸誘導体
FR2687574A1 (fr)	1993-08-27	Nouvelle application therapeutique de derives du pyridylpyrrolothiazole carboxamide.
JPS5899458A (ja)	1983-06-13	クロルヘキシジンジナプロキセネ−ト誘導体、その製造方法およびそれを有効成分とする抗炎症、殺菌および抗細菌剤
US3946006A (en)	1976-03-23	Tetrahydrothiadiazinethiones
JPS62255426A (ja)	1987-11-07	抗菌性組成物
JPS6365641B2 (2)	1988-12-16
BE898603A (fr)	1984-07-04	Esters de type penem, procede pour les preparer, medicament les contenant
BE856243A (fr)	1977-12-29	Nouveaux composes de penicilline
EP2668164A1 (fr)	2013-12-04	Nouveaux derives d'azacoumarines presentant une activite inhibitrice des pompes mdr
FR2607135A1 (fr)	1988-05-27	Nouveaux derives des cephalosporines a pharmacocinetique amelioree, procede pour leur preparation et compositions pharmaceutiques les contenant
JPWO2020045653A5 (2)	2022-11-08